<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="about.html">About</a>
            <a href="index.html">Index</a>
        </div>
    <div class="header"><h3>LEADER</h3></div><p><span class="main">"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes".The New England Journal of Medicine. 2016. </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/LEADER>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa1603827>Full Journal Article</a>
                                        </span></p><p><span class="main">Contents:
 </span></p><p><span class="main">1. Clinical Question
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">6.1 Inclusion Criteria
 </span></p><p><span class="main">6.2 Exclusion Criteria
 </span></p><p><span class="main">6.3 Baseline Characteristics
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Does the addition of liraglutide to standard care improve cardiovascular outcomes in patients with type 2 diabetes and high cardiovascular risk?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Among patients with type 2 diabetes and high cardiovascular risk, liraglutide added to standard care reduced the risk of major cardiovascular events and death from any cause.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Liraglutide, a glucagon-like peptide 1 analogue, showed efficacy in lowering glucose levels and was associated with reductions in weight and blood pressure. The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial aimed to assess liraglutide's long-term effect on cardiovascular outcomes in high-risk type 2 diabetes patients.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">As of this trial's publication, no guidelines have been updated to reflect the results of this study.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Multicenter, double-blind, placebo-controlled, randomized controlled trial. 
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">N=9,340 patients with type 2 diabetes and high cardiovascular risk.
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Patients were randomized to receive either 1.8 mg (or the maximum tolerated dose) of liraglutide or a placebo once daily as a subcutaneous injection in addition to standard care.
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- The composite of first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke occurred significantly less in the liraglutide group compared with the placebo group.
- Death from cardiovascular causes and death from any cause were also lower in the liraglutide group.
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Nonsignificant reductions were seen with liraglutide compared to placebo for nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure.
- Fewer microvascular events were observed in the liraglutide group.
- Adverse events leading to discontinuation of liraglutide were mainly gastrointestinal.
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">Funded by Novo Nordisk and grants from the National Institutes of Health.
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main"> </span></p><p><span class="main">For full details of the study, readers should refer to the original publication and supplementary materials provided by the New England Journal of Medicine. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>